Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Sell
40
ATNM Quote, Financials, Valuation and Earnings
Last price:
$1.19
Seasonality move
:
5.17%
Day range:
$1.18 - $1.30
52-week range:
$1.03 - $10.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.97x
Volume:
229.1K
Avg. volume:
158.4K
1-year change:
-81.8%
Market cap:
$37.1M
Revenue:
$81K
EPS (TTM):
-$1.39
Analysts' Opinion
-
Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Actinium Pharmaceuticals has an estimated upside of 320.17% from its current price of $1.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing -68.07% downside risk from its current price of $1.19.
Fair Value
-
According to the consensus of 3 analysts, Actinium Pharmaceuticals has 320.17% upside to fair value with a price target of $5.00 per share.
ATNM vs. S&P 500
-
Over the past 5 trading days, Actinium Pharmaceuticals has overperformed the S&P 500 by 2.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Actinium Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Actinium Pharmaceuticals revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Actinium Pharmaceuticals reported revenues of $81K.
Earnings Growth
-
Actinium Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Actinium Pharmaceuticals reported earnings per share of -$0.37.
Enterprise value:
-41.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
1.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-50.26%
Net Income Margin (TTM):
--
Return On Equity:
-95.08%
Return On Invested Capital:
-95.08%
Operating Margin:
-12769.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$30.9M | -$52.9M | -$45M | -$14.4M | -$12.6M | |
| EBITDA | -$30.2M | -$52.1M | -$44.2M | -$14.2M | -$12.4M | |
| Diluted EPS | -$1.30 | -$1.93 | -$1.39 | -$0.49 | -$0.37 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49.2M | $83.3M | $113.4M | $85.6M | $79.5M | |
| Total Assets | $50.5M | $84.5M | $116.8M | $88.9M | $82.1M | |
| Current Liabilities | $4.7M | $4.2M | $8.4M | $8.7M | $7.8M | |
| Total Liabilities | $5.1M | $4.2M | $45.6M | $45.4M | $43.9M | |
| Total Equity | $45.4M | $80.3M | $71.3M | $43.6M | $38.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $11.4M | -$47.6M | -$34.8M | -$11.1M | -$12M | |
| Cash From Investing | -$350K | -$169K | -$11K | -$30K | -- | |
| Cash From Financing | $19M | $18.6M | $30.5M | $2.9M | $4.6M | |
| Free Cash Flow | $11M | -$47.8M | -$34.8M | -$11.2M | -$12M | |
ATNM
Sector
Market Cap
$37.1M
$37.4M
Price % of 52-Week High
11.62%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
-10.41%
-0.75%
1-Year Price Total Return
-81.8%
-38.36%
Beta (5-Year)
0.105
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.19
200-day SMA
Sell
Level
$2.93
Bollinger Bands (100)
Sell
Level
1.12 - 1.6
Chaikin Money Flow
Sell
Level
-162.8M
20-day SMA
Buy
Level
$1.17
Relative Strength Index (RSI14)
Buy
Level
51.04
ADX Line
Buy
Level
10.75
Williams %R
Neutral
Level
-40.6204
50-day SMA
Sell
Level
$1.21
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
246.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.0086)
Sell
CA Score
(Annual)
Level (-2.7401)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.763)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Stock Forecast FAQ
In the current month, ATNM has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ATNM average analyst price target in the past 3 months is $5.00.
-
Where Will Actinium Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Actinium Pharmaceuticals share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Actinium Pharmaceuticals?
Analysts are divided on their view about Actinium Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Actinium Pharmaceuticals is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Actinium Pharmaceuticals's Price Target?
The price target for Actinium Pharmaceuticals over the next 1-year time period is forecast to be $5.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ATNM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Actinium Pharmaceuticals is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ATNM?
You can purchase shares of Actinium Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Actinium Pharmaceuticals shares.
-
What Is The Actinium Pharmaceuticals Share Price Today?
Actinium Pharmaceuticals was last trading at $1.19 per share. This represents the most recent stock quote for Actinium Pharmaceuticals. Yesterday, Actinium Pharmaceuticals closed at $1.19 per share.
-
How To Buy Actinium Pharmaceuticals Stock Online?
In order to purchase Actinium Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
52
RGC alert for Mar 19
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Sell
46
CVNA alert for Mar 19
Carvana [CVNA] is down 10.69% over the past day.
Buy
93
ESLT alert for Mar 19
Elbit Systems [ESLT] is up 10.52% over the past day.
